BioAffinity Technologies, Current Debt
BIAF Stock | USD 1.25 0.01 0.81% |
At this time, BioAffinity Technologies,'s Total Debt To Capitalization is most likely to increase significantly in the upcoming years. The BioAffinity Technologies,'s current Debt Equity Ratio is estimated to increase to 0.1, while Net Debt is forecasted to increase to (1.2 M). . BioAffinity Technologies,'s financial risk is the risk to BioAffinity Technologies, stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.05597131 | Current Value 0.0532 | Quarterly Volatility 16.67643709 |
BioAffinity |
BioAffinity Technologies, Financial Rating
bioAffinity Technologies, financial ratings play a critical role in determining how much BioAffinity Technologies, have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for BioAffinity Technologies,'s borrowing costs.Piotroski F Score | 5 | Healthy | View |
Beneish M Score | (4.45) | Unlikely Manipulator | View |
bioAffinity Technologies, Debt to Cash Allocation
Many companies such as BioAffinity Technologies,, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
bioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity.BioAffinity Technologies, Total Assets Over Time
BioAffinity Technologies, Assets Financed by Debt
The debt-to-assets ratio shows the degree to which BioAffinity Technologies, uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.BioAffinity Technologies, Debt Ratio | 5.32 |
BioAffinity Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning BioAffinity Technologies, Use of Financial Leverage
BioAffinity Technologies,'s financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures BioAffinity Technologies,'s total debt position, including all outstanding debt obligations, and compares it with BioAffinity Technologies,'s equity. Financial leverage can amplify the potential profits to BioAffinity Technologies,'s owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if BioAffinity Technologies, is unable to cover its debt costs.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 1.6 M | 1.5 M | |
Net Debt | -1.2 M | -1.2 M | |
Short Term Debt | 920.3 K | 874.3 K | |
Long Term Debt | 184.2 K | 117.5 K | |
Short and Long Term Debt | 226.6 K | 215.2 K | |
Net Debt To EBITDA | 0.16 | 0.17 | |
Debt To Equity | 0.09 | 0.10 | |
Interest Debt Per Share | 0.06 | 0.05 | |
Debt To Assets | 0.06 | 0.05 | |
Long Term Debt To Capitalization | (0.01) | (0.01) | |
Total Debt To Capitalization | 0.09 | 0.09 | |
Debt Equity Ratio | 0.09 | 0.10 | |
Debt Ratio | 0.06 | 0.05 | |
Cash Flow To Debt Ratio | (13.12) | (13.78) |
Currently Active Assets on Macroaxis
When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:Check out the analysis of BioAffinity Technologies, Fundamentals Over Time. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.